Pharmacological management of sepsis in adults with a focus on the current gold standard treatments and promising adjunctive strategies: evidence from the last five years

References

• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–810.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans L, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–377.
   PubMed Web of Science ®Google Scholar
• Raith EP, Udy AA, Bailey M, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317:290–300.
   PubMed Web of Science ®Google Scholar
• Donnelly JP, Safford MM, Shapiro NI, et al. Application of the third international consensus definitions for sepsis (Sepsis-3) classification: a retrospective population-based cohort study. Lancet Infect Dis. 2017;17:661–670.
   PubMed Web of Science ®Google Scholar
• Park HK, Kim WY, Kim MC, et al. Quick sequential organ failure assessment compared to systemic inflammatory response syndrome for predicting sepsis in emergency department. J Crit Care. 2017;42:12–17.
   PubMed Web of Science ®Google Scholar
• Askim A, Moser F, Gustad LT, et al. Poor performance of quick-SOFA (qSOFA) score in predicting severe sepsis and mortality – a prospective study of patients admitted with infection to the emergency department. Scand J Trauma Resusc Emerg Med. 2017;25:56.
   PubMed Web of Science ®Google Scholar
• Tusgul S, Carron PN, Yersin B, et al. Low sensitivity of qSOFA, SIRS criteria and sepsis definition to identify infected patients at risk of complication in the prehospital setting and at the emergency department triage. Scand J Trauma Resusc Emerg Med. 2017;25:108.
   PubMed Web of Science ®Google Scholar
• Haydar S, Spanier M, Weems P, et al. Comparison of QSOFA score and SIRS criteria as screening mechanisms for emergency department sepsis. Am J Emerg Med. 2017;35:1730–1733.
   PubMed Web of Science ®Google Scholar
• Finkelsztein EJ, Jones DS, Ma KC, et al. Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit. Crit Care. 2017;21:73.
   PubMed Web of Science ®Google Scholar
• April MD, Aguirre J, Tannenbaum LI, et al. Sepsis clinical criteria in emergency department patients admitted to an intensive care unit: an external validation study of quick sequential organ failure assessment. J Emerg Med. 2017;52:622–631.
   PubMed Web of Science ®Google Scholar
• Churpek MM, Snyder A, Han X, et al. Quick sepsis-related organ failure assessment, systemic inflammatory response syndrome, and early warning scores for detecting clinical deterioration in infected patients outside the intensive care unit. Am J Respir Crit Care Med. 2017;195:906–911.
   PubMed Web of Science ®Google Scholar
• Boulos D, Shehabi Y, Moghaddas JA, et al. Predictive value of quick sepsis-related organ failure scores following sepsis-related medical emergency team calls: a retrospective cohort study. Anaesth Intensive Care. 2017;45:688–694.
   PubMed Web of Science ®Google Scholar
• Rudd KE, Seymour CW, Aluisio AR, et al. Association of the quick sequential (sepsis-related) organ failure assessment (qSOFA) score with excess hospital mortality in adults with suspected infection in low- and middle-income countries. JAMA. 2018;319:2202–2211.
   PubMed Web of Science ®Google Scholar
• Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:762–774.
   PubMed Web of Science ®Google Scholar
• Williams JM, Greenslade JH, McKenzie JV, et al. Systemic inflammatory response syndrome, quick sequential organ function assessment, and organ dysfunction: insights from a prospective database of ED patients with infection. Chest. 2017;151:586–596.
   PubMed Web of Science ®Google Scholar
• Solligård E, Damås JK. SOFA criteria predict infection-related in-hospital mortality in ICU patients better than SIRS criteria and the qSOFA score. Evid Based Med. 2017;22:211.
   PubMedGoogle Scholar
• Giamarellos-Bourboulis EJ, Tsaganos T, Tsangaris I, et al. Validation of the new sepsis-3 definitions: proposal for improvement in early risk identification. Clin Microbiol Infect. 2017;23:104–109.
   PubMed Web of Science ®Google Scholar
• Freund Y, Lemachatti N, Krastinova E, et al. Prognostic accuracy of sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department. JAMA. 2017;317:301–308.
   PubMed Web of Science ®Google Scholar
• González Del Castillo J, Julian-Jiménez A, González-Martínez F, et al. Prognostic accuracy of SIRS criteria, qSOFA score and GYM score for 30-day-mortality in older non-severely dependent infected patients attended in the emergency department. Eur J Clin Microbiol Infect Dis. 2017;36:2361–2369.
   PubMed Web of Science ®Google Scholar
• Maitra S, Som A, Bhattacharjee S. Accuracy of quick sequential organ failure assessment (qSOFA) score and systemic inflammatory response syndrome (SIRS) criteria for predicting mortality in hospitalized patients with suspected infection: a meta-analysis of observational studies. Clin Microbiol Infect. 2018. DOI:10.1016/j.cmi.2018.03.032.
   PubMed Web of Science ®Google Scholar
• Serafim R, Gomes JA, Salluh J, et al. A comparison of the quick-SOFA and systemic inflammatory response syndrome criteria for the diagnosis of sepsis and prediction of mortality. Chest. 2018;153:646–655.
   PubMed Web of Science ®Google Scholar
• Murri R, Taccari F, Palazzolo C, et al. IDSA did not endorse the surviving sepsis campaign guidelines. Clin Infect Dis. 2018;66:1815–1816.
   PubMed Web of Science ®Google Scholar
• The PRISM Investigators. Early, goal-directed therapy for septic shock - a patient-level meta-analysis. N Engl J Med. 2017;376:2223–2234.
   PubMed Web of Science ®Google Scholar
• Pruinelli L, Westra BL, Yadav P, et al. Delay within the 3-hour surviving sepsis campaign guideline on mortality for patients with severe sepsis and septic shock. Crit Care Med. 2018;46:500–505.
   PubMed Web of Science ®Google Scholar
• Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017;376:2235–2244.
   PubMed Web of Science ®Google Scholar
• Bednarczyk JM, Fridfinnson JA, Kumar A, et al. Incorporating dynamic assessment of fluid responsiveness into goal-directed therapy: a systematic review and meta-analysis. Crit Care Med. 2017;45:1538–1545.
   PubMed Web of Science ®Google Scholar
• Peker N, Couto N, Sinha B, et al. Diagnosis of bloodstream infections from positive blood cultures and directly from blood samples: recent developments in molecular approaches. Clin Microbiol Infect. 2018;24:944–955.
   PubMed Web of Science ®Google Scholar
• Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749–1755.
   PubMed Web of Science ®Google Scholar
• Koupetori M, Retsas T, Antonakos N, et al. Bloodstream infections and sepsis in Greece: over-time change of epidemiology and impact of de-escalation on final outcome. BMC Infect Dis. 2014;14:272.
   PubMed Web of Science ®Google Scholar
• Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, et al. Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum β-lactamase-producing enterobacteriaceae: results from the INCREMENT cohort. Clin Infect Dis. 2017;65:1615–1623.
   PubMed Web of Science ®Google Scholar
• Justo JA, Bookstaver PB, Kohn J, et al. Combination therapy vs monotherapy for Gram-negative bloodstream infection: matching by predicted prognosis. Int J Antimicrob Agents. 2018;51:488–492.
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56:236–244.
   PubMed Web of Science ®Google Scholar
• Carrié C, Petit L, d’Houdain N, et al. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study. Int J Antimicrob Agents. 2018;51:443–449.
   PubMed Web of Science ®Google Scholar
• Borsuk-de-Moor A, Rypulak E, Potrḙć B, et al. Population pharmacokinetics of high-dose tigecycline in patients with sepsis or septic shock. Antimicrob Agents Chemother. 2018;62:e02273–17.
   PubMed Web of Science ®Google Scholar
• Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56:4241–4249.
   PubMed Web of Science ®Google Scholar
• Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20:O117–23.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391–400.
   PubMed Web of Science ®Google Scholar
• Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2017;64:565–571.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61:e00883–17.
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–295.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788–799.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–2179.
   PubMed Web of Science ®Google Scholar
• Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018;22:191.
   PubMed Web of Science ®Google Scholar
• Gordon AC, Mason AJ, Perkins GD, et al. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med. 2014;42:1325–1333.
   PubMed Web of Science ®Google Scholar
• Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016;375:1638–1648.
   PubMed Web of Science ®Google Scholar
• Meng JB, Hu MH, Lai ZZ, et al. Levosimendan versus dobutamine in myocardial injury patients with septic shock: a randomized controlled trial. Med Sci Monit. 2016;22:148696.
   Web of Science ®Google Scholar
• Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419–430.
   PubMed Web of Science ®Google Scholar
• Avni T, Lador A, Lev S, et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One. 2015;10:e0129305.
   PubMedGoogle Scholar
• Annane D, Pastores SM, Rochweg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): society of critical care medicine (SCCM) and European society of intensive care medicine (ESICM). Crit Care Med. 2017;45:2078–2088.
   PubMed Web of Science ®Google Scholar
• Póvoa P, Salluh JI, Martinez ML, et al. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. Crit Care. 2015;19:193.
   PubMed Web of Science ®Google Scholar
• Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378:797–808.
   PubMed Web of Science ®Google Scholar
• Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378:809–818.
   PubMed Web of Science ®Google Scholar
• Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20:329.
   PubMed Web of Science ®Google Scholar
• Katsenos CS, Antonopoulou AN, Apostolidou EN, et al. Early administration of hydrocortisone replacement after the advent of septic shock: impact on survival and immune response. Crit Care Med. 2014;42:1651–1657.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Apostolidou E, Lada M, et al. Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Crit Care. 2013;17:R247.
   PubMed Web of Science ®Google Scholar
• Cavazzuti I, Serafini G, Busani S, et al. Early therapy with Igm-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med. 2014;40:1888–1896.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Tziolos N, Routsi C, et al. Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins. Clin Microbiol Infect. 2016;22:499–506.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Fushimi K, et al. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide stydy. Clin Infect Dis. 2015;61:385–392.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Fushimi K, et al. Intravenous immunoglobulin use in septic shock patients after emergency laparotomy. J Infect. 2015;71:158–166.
   PubMed Web of Science ®Google Scholar
• Ishikura H, Nakamura Y, Kawano Y, et al. Intravenous immunoglobulin improves sepsis-induced coagulopathy: A retrospective, single-center observational study. J Crit Care. 2015;30:579–583.
   PubMed Web of Science ®Google Scholar
• Toth I, Mikor A, Leiner T, et al. Effects of IgM-enriched immunoglobulin therapy in septic-shock-induced multiple organ failure: pilot study. J Anesth. 2013;27:618–622.
   PubMed Web of Science ®Google Scholar
• Welte T, Dellinger RP, Ebelt H, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018;44:438–448.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Marshall JC, Dellinger RP, et al. Talactoferrin in severe sepsis results from the phase II/III oral talactoferrin in severe sepsis trial. Crit Care Med. 2015;43:1832–1838.
   PubMed Web of Science ®Google Scholar
• Bernard GR, François B, Mira JP, et al. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study. Crit Care Med. 2014;42:504–511.
   PubMed Web of Science ®Google Scholar
• Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: re-analysis of a prior phase III trial. Crit Care Med. 2016;44:275–281.
   PubMed Web of Science ®Google Scholar
• Uchida M, Abe T, Ono K, et al. Ulinastatin did not reduce mortality in elderly multiple organ failure patients: a retrospective observational study in a single center ICU. Acute Med Surg. 2017;5:90–97.
   PubMed Web of Science ®Google Scholar
• Karnad DR, Bhadade R, Verma PK, et al. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis a multicenter randomized controlled study. Intensive Care Med. 2014;40:830–838.
   PubMed Web of Science ®Google Scholar
• Sehgal IS, Agarwal R, Aggarwal AN, et al. A randomized trial of mycobacterium w in severe sepsis. J Crit Care. 2015;30:85–89.
   PubMed Web of Science ®Google Scholar
• Marik PE, Khangoora V, Rivera R, et al. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock. a retrospective before-after study. Chest. 2017;151:1229–1238.
   PubMed Web of Science ®Google Scholar
• Woth G, Nagy B, Merei A, et al. The effect of Na-selenite treatment on the oxidative stress-antioxidants balance of multiple organ failure. J Crit Care. 2014;29:883.e7-11.
   PubMed Web of Science ®Google Scholar
• Donnino MW, Mortensen SJ, Andersen LW, et al. Ubiquinol (reduced coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial. Crit Care. 2015;19:275.
   PubMed Web of Science ®Google Scholar
• Janz DR, Bastarache JA, Rice TW, et al. randomized, placebo-controlled trial of acetaminophen for the reduction of oxidative injury in severe sepsis: the ACROSS trial. Crit Care Med. 2015;43:534–541.
   PubMed Web of Science ®Google Scholar
• Pickkers P, Mehta RL, Murray PT, et al. Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: a randomized clinical trial. JAMA. 2018;320:1998–2009
   PubMed Web of Science ®Google Scholar
• Beed M, Brindley PG, Mahajan R, et al. The association between prior statin use and long-term outcomes after critical care admission. J Crit Care. 2016;35:63–68.
   PubMed Web of Science ®Google Scholar
• Lee CC, Lee MG, Hsu TC, et al. A population-based cohort study on the drug-specific effect of statins on sepsis outcome. Chest. 2018;153:805–815.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Horiguchi H, et al. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost. 2014;12:1470–1479.
   PubMed Web of Science ®Google Scholar
• Yasuda N, Goto K, Ohchi Y, et al. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation. J Crit Care. 2016;36:29–34.
   PubMed Web of Science ®Google Scholar
• Preliminary results of overseas phase III clinical study for ART-123. [cited 2019 Feb 4]. Available at: https://www.asahi-kasei.co.jp/asahi/en/news/2018/e180802.html
   Google Scholar
• Wu Q, Ren J, Wu X, et al. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study. J Crit Care. 2014;29:362–366.
   PubMed Web of Science ®Google Scholar
• Al Harbi SA, Tamim HM, Al-Dorzi HM, et al. Association between aspirin therapy and the outcome in critically ill patients: a nested cohort study. BMC Pharmacol Toxicol. 2016;17:5.
   PubMed Web of Science ®Google Scholar
• Wiewel MA, de Stoppelaar SF, van Vught LA, et al. Chronic antiplatelet therapy is not associated with alterations in the presentation, outcome, or host response biomarkers during sepsis: a propensity-matched analysis. Intensive Care Med. 2016;42:352–360.
   PubMed Web of Science ®Google Scholar
• Tsaganos T, Raftogiannis M, Pratikaki M, et al. Clarithromycin leads to long-term survival and cost benefit in ventilator-associated pneumonia and sepsis. Antimicrob Agents Chemother. 2016;60:3640–3646.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Mylona V, Antonopoulou A, et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother. 2014;69:1111–1118.
   PubMed Web of Science ®Google Scholar
• Kyriazopoulou K, Leventogiannis K, Norrby-Teglund A, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017;15:172.
   PubMed Web of Science ®Google Scholar
• Meyer NJ, Reilly JP, Anderson BJ, et al. Mortality benefit of recombinant human interleukin-1 receptor antagonist for sepsis varies by initial interleukin-1 receptor antagonist plasma concentration. Crit Care Med. 2018;46:21–28.
   PubMed Web of Science ®Google Scholar
• Kumar S, Gupta E, Kaushik S, et al. Evaluation of oxidative stress and antioxidant status: correlation with the severity of sepsis. Scand J Immunol. 2018;87:e12653.
   PubMed Web of Science ®Google Scholar
• Fowler AA, Syed AA, Knowlson S, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med. 2014;12:32.
   PubMed Web of Science ®Google Scholar
• Christodoulou S, Kyriazopoulou K, Chrysanthakopoulou M, et al. Lipid peroxidation in Gram-negative bacteremia modulates the risk for septic shock and infections by resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2017;36:2171–2177.
   PubMed Web of Science ®Google Scholar
• Choudhury S, Kannan K, Addison MP, et al. Combined treatment with atorvastatin and imipenem improves survival and vascular functions in mouse model of sepsis. Vascul Pharmacol. 2015;71:139–150.
   PubMed Web of Science ®Google Scholar
• Wiewel MA, Scicluna BP, van Vught LA, et al. The host response in critically ill sepsis patients on statin therapy: a prospective observational study. Ann Intensive Care. 2018;8:9.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–874.
   PubMed Web of Science ®Google Scholar
• Leentjens J, Kox M, Koch RM, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012;186:838–845.
   PubMed Web of Science ®Google Scholar
• Venet B, Demart J, Blaise BJ, et al. IL-7 restores T lymphocyte immunometabolic failure in septic shock patients through mTOR activation. J Immunol. 2017;199:1606–1615.
   PubMed Web of Science ®Google Scholar
• Francois B, Jeannet R, Daix T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3:e98960.
   PubMed Web of Science ®Google Scholar
• Nie W, Li B, Xiu Q. β-lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:1441–1446.
   PubMed Web of Science ®Google Scholar
• Horita N, Otsuka T, Haranaga S, et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis. Respirology. 2016;21:1193–1200.
   PubMed Web of Science ®Google Scholar
• Garin N, Genné D, Carballo S, et al. β-lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174:1894–1901.
   PubMed Web of Science ®Google Scholar
• McIntyre LA, Stewart DJ, Mei SHJ, et al. Cellular immunotherapy for septic shock. a phase I clinical trial. Am J Respir Crit Care Med. 2018;197:337–347.
   PubMed Web of Science ®Google Scholar
• He X, Ai S, Guo W, et al. Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: a phase 1 clinical trial. Transl Res. 2018;199:52–61.
   PubMed Web of Science ®Google Scholar